Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
22 sept. 2023 16h30 HE
|
Achilles Therapeutics PLC
LONDON, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal...
Achilles Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights
04 août 2023 07h00 HE
|
Achilles Therapeutics PLC
- Clinical and translational science data expected in the fourth quarter of 2023 from the ongoing Phase I/IIa trials in NSCLC and melanoma - - neoRanker™ immunogenicity prediction module of PELEUS™...
Achilles Therapeutics to Present at Upcoming Conferences
12 juin 2023 08h00 HE
|
Achilles Therapeutics PLC
LONDON, June 12, 2023 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies to treat solid tumors,...
Achilles Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights
10 mai 2023 07h15 HE
|
Achilles Therapeutics PLC
- Phase I/IIa clinical trials in NSCLC and melanoma progressing with additional clinical and translational science data expected in the fourth quarter of 2023 - - Strong cash position of $158.5...
Achilles Therapeutics’ New Immunogenicity Prediction Application of its AI-Powered PELEUS™ Platform Uniquely Identifies the Most Potent T Cell Antigens
10 mai 2023 07h00 HE
|
Achilles Therapeutics PLC
LONDON, May 10, 2023 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal...
Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
25 avr. 2023 18h00 HE
|
Achilles Therapeutics PLC
LONDON, April 25, 2023 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal...
Achilles Therapeutics Announces Grant of US Patent Covering the Treatment of Patients with an Immunotherapy Targeting Neoantigens Based on Tumor HLA Status
25 avr. 2023 07h00 HE
|
Achilles Therapeutics PLC
- Patent broadly covers technology to select neoantigens that are presented by HLA molecules determined to be present in a patient’s tumor - - Patent applies to any modality, including vaccine and...
DelveInsight Highlights Major Advances, Transformative Therapies, and 80+ Leading Players Wheeling the Crohn's Disease Pipeline Landscape
17 avr. 2023 13h00 HE
|
DelveInsight Business Research LLP
New York, USA, April 17, 2023 (GLOBE NEWSWIRE) -- DelveInsight Highlights Major Advances, Transformative Therapies, and 80+ Leading Players Wheeling the Crohn's Disease Pipeline Landscape Crohn’s...
Achilles Therapeutics to Present at Chardan’s 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
17 avr. 2023 08h00 HE
|
Achilles Therapeutics PLC
LONDON, April 17, 2023 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies to treat solid...
Inflammatory Bowel Disease Treatment Market Size, Share & Trends Analysis Report By Type, By Drug Class, By Route Of Administration, By Distribution Channel, By Region And Segment Forecasts, 2023 - 2030
09 mars 2023 06h21 HE
|
ReportLinker
New York, March 09, 2023 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Inflammatory Bowel Disease Treatment Market Size, Share & Trends Analysis Report By Type, By...